key: cord-0846854-l1hvft7n
authors: Kim, Sae-Hoon; Ji, Eunjeong; Won, Seung-Hyun; Cho, Jungwon; Kim, Yong-Hyun; Ahn, Soyeon; Chang, Yoon-Seok
title: Association of asthma comorbidity with poor prognosis of coronavirus disease 2019
date: 2021-08-16
journal: World Allergy Organ J
DOI: 10.1016/j.waojou.2021.100576
sha: a609286e5866d189b1069951b17fa8f7dd4ed7a4
doc_id: 846854
cord_uid: l1hvft7n

Background While global health agencies have listed asthma as a vulnerability for severe cases of coronavirus disease 2019 (COVID-19), the evidence supporting this is scarce. Methods A nationwide cohort study was conducted using the validated Korean national health insurance claim data of patients diagnosed with COVID-19 between January 1 and April 8, 2020. Asthma comorbidity was determined using a diagnosis code assigned by the physician and the prescription of asthma-related medications. The clinical course of COVID-19 was classified into three severity grades according to the requirements for oxygen supply and mechanical ventilation. We also evaluated the association of asthma with overall and in-hospital mortality of COVID-19. Results Asthma morbidity was a significant risk factor for severe COVID-19 (grade 2 requiring oxygen supply) (adjusted odds ratio [aOR]=1.341, 95% confidence interval [CI], 1.051−1.711, P=0.018) and grade 3 requiring mechanical ventilation or leading to death (aOR=1.723, 95% CI: 1.230−2.412, P=0.002) multinomial logistic regression adjusting co-risk factors. Asthma was also significantly associated with mortality of COVID-19 (aOR=1.453, 95% CI: 1.015−2.080, P=0.041) and was revealed to have a shorter time to in-hospital mortality of COVID-19 (P<0.001). Patients with recent asthma exacerbation showed more severe COVID-19 of grade 3 (OR=7.371, 95% CI: 2.018−26.924, P=0.003) and higher mortality (OR=9.208, 95% CI: 2.597−32.646, P<0.001) in univariable analysis, but the statistical significance was not found in multivariable analysis. Conclusion Asthma morbidity was associated with severity and mortality of COVID-19. Patients with asthma should pay more attention to avoid worsening of COVID-19.

The novel coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute 26 respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major challenge for global healthcare 27 systems worldwide. The World Health Organization has listed airway disease as a vulnerable 28 condition for COVID-19 along with diabetes and heart disease, and the Centers for Disease 29

Control and Prevention announced that moderate to severe asthma may lead to higher risk of 30 serious cases of COVID-19. 1,2 COVID-19 may cause pneumonia, acute respiratory diseases, 31 and lead to asthma attacks because respiratory viral infections are the most common triggers 32 of asthma exacerbation. Patients with asthma also showed impaired production of antiviral 33 interferons (IFNs). 3 However, early reports of COVID-19 did not indicate asthma as a risk 34 factor of infection or severe illness with the virus. 4,5 Although the evidence for asthma as a 35 risk for COVID-19 is scarce, a contradictory hypothesis that asthma might be protective 36 against COVID-19 has also been suggested. 6 SARS-CoV-2 uses angiotensin-converting 37 enzyme 2 (ACE2) for cell entry in the airway epithelial cells. 7 In recent reports, airway 38 epithelial cells from patients with allergy or asthma showed lower expression of ACE2, and 39 ACE2 expression was inversely correlated with type 2 (T2) cytokine levels and T2 signature 40 molecular expression. 8, 9 Moreover, patients with COVID-19 having poor outcomes showed 41 early robust type I interferon expression together with a high level of IFN-related chemokine 42 and IFN-γ. 10 Based on these reports, an intriguing clinical question has been raised about 43 whether patients with asthma who have lower production of IFNs and higher T2 cytokines 44 might have better outcomes than healthy individuals. 6 45

This study aimed to investigate whether the comorbidity of asthma affects the clinical 46 outcomes of COVID-19 in a retrospective cohort study using nationwide population-based claim data from the Korean National Health Insurance Service (NHIS). status, we evaluated asthma control status indirectly using a history of asthma exacerbations 71 requiring emergency department visits in the last year. Cases of asthma exacerbation were 72 detected from the claims data for the prescription of salbutamol sulfate medication among 73 those claimed by the code of emergency medical care. The comorbidity index was evaluated 74 with comorbid diseases used in the Charlson Comorbidity Index (CCI) criteria, except asthma, 75 and categorized into none and one or more (≥1). Comorbidity data were assessed using the 76 ICD-10 codes recorded during the past year for each patient. 77

The severity of the SARS-CoV-2 infection was classified into three severity grades 79 according to the requirements for oxygen supply and mechanical ventilation. Grade 1 was 80 defined as no requirement for oxygen supply. Grade 2 was the requirement of oxygen supply 81 

A total of 7,590 patients diagnosed with COVID-19 between January 1 and April 8, 2020, 101

were enrolled in the study. The mean age was 45.9, and 3,095 patients (40.8%) were male. 102

The twenties were the largest age group (24.4%), and elderly over the age of 65 accounted for 103

18.0% of the study population. The most common area of residence was Daegu/Kyungbuk 104 (54.2%), which was the first endemic area of COVID-19 in South Korea between February 105

and March 2020. The mortality rate of this population was 3.0% in the study period and 2.7% 106 died in hospitals. Patients with any type of comorbidity indicated in the CCI other than 107 asthma, were 49.5%. According to the working definition of asthma, 764 patients (10.1%) 108

were classified into the asthma group, and the others were classified into the control group 109 (Supplementary figure 1). The mean age and proportion of female patients were significantly 110 higher in the asthma group than in the control group. The asthma group showed higher rates 111 of residence in Daegu/Kyungbuk and diagnosis in February 2020, the first endemic area and 112 endemic period of COVID-19 in South Korea, respectively. Comorbidities including 113 myocardial infarction, heart failure, cerebrovascular diseases, chronic respiratory diseases 114 other than asthma, diabetes, liver disease, and renal diseases were more common in the 115 asthma group than in the control group (Table 1) . 116

Patients with asthma showed a more severe form of COVID-19 infection. Grade 2 severity 118 of COVID-19 requiring oxygen therapy and grade 3 severity of COVID-19 requiring 119 mechanical ventilation and leading to death were significantly more prevalent in the asthma 120 group than in the control group. The crude mortality rate was also significantly higher in patients with COVID-19 and asthma than in the controls (6.3% vs. 2.6%, OR=2.489, 122 P<0.001) ( Figure 1A) . 131

Among the 764 patients with asthma, 11 were determined to have recent asthma 133 exacerbation requiring emergency department visits according to our working criteria. 134

Patients with recent asthma exacerbation showed a more severe case of COVID-19, grade 3 135 requiring mechanical ventilation, (OR=7.371, P=0.003) and higher mortality (OR=9.208, 136

Since old age was the dominant risk factor for the severity of COVID-19, we additionally 144 performed a subgroup analysis in elderly patients over the age of 65. Here, asthma morbidity 145 was significantly associated with grade 2 (OR=1.454, P=0.031) and grade 3 (OR=1.749, 146 P=0.004) of severe COVID-19 and mortality of COVID-19 (OR=1.619, P=0.012). In the 147 multivariable analysis, asthma morbidity was a significant risk factor for grade 3 disease 148 along with other risk factors including age, sex, residence in Daegu/Kyungbuk, and 149 comorbidity (adjusted OR=1.563, P=0.032). However, statistical significance was not found 150 in the multivariable analysis for grade 2 severity and mortality in the subgroup analysis of the 151 elderly (Table 5) . COVID-19 is a major threat to global health, and asthma is considered a risk factor for 155 severe cases of COVID-19. However, the evidence for the effect of asthma on COVID-19 has 156 not been well demonstrated. Our study revealed that asthma morbidity is associated with 157 more severe disease and mortality of COVID-19. These findings were demonstrated even in 158 the multivariable analysis adjusting for other confounding risk factors such as age, residence 159 in endemic areas, comorbidities, and subgroup analysis confined to the elderly. Moreover, 160 patients with uncontrolled asthma who had experienced asthma exacerbations requiring 161 emergency department visits in the past year showed a greater risk of severe COVID-19, 162

higher mortality rate and shorter time to in-hospital mortality of COVID-19, although the 163 uncontrolled asthma was not independent risk factor in the multivariate analysis. Our results 164 indicate special caution for severe cases of COVID-19 in patients with asthma, especially in 165 those with a history of recent asthma exacerbation. 166

The COVID-19 pandemic is an ongoing global health issue. Until December 2020, more 167 than 79 million COVID-19 cases have been reported with over 1.7 million deaths 168 worldwide. 11 SARS-CoV-2 is a respiratory pathogenic virus, and whether the morbidity of 169 asthma, a common respiratory disease, affects COVID-19 in terms of disease incidence and 170 severity is under debate. Early studies have not indicated a high prevalence of asthma in 171 patients with COVID-19. According to China, no patient with COVID-19 was reported to 172 have asthma as a comorbidity. 4,5 A study from Italy also reported a low prevalence of asthma 173 (<3%). 12 However, a recent report from the CDC showed a high prevalence of asthma in 174 patients hospitalized with COVID-19 in the United States. Asthma was present in about 17% 175 of all admitted patients and its prevalence was as high as 27% in the 2049 years age group. 13 176

In our study population, the overall prevalence of asthma (according to our working population. This seems to be related to our definition of asthma, which includes patients with 179 a history of asthma treatment within the last 3 years. The prevalence of current asthma in 180 patients who had an asthma diagnosis with simultaneous asthma medication history in the 181 past year was 5.3% (data not shown); this was similar to previous reports of asthma 182 prevalence in the general population. 14 It is unclear whether a patient with asthma is more The phenotype of asthma, for example, allergic or nonallergic, childhood-onset, or adult-211 onset, might affect the acquisition and outcome of COVID-19 in connection with ACE2 212

Regarding another mechanism of interaction between asthma and COVID-19, patients with 214 asthma have an impaired antiviral response, which potentially triggers asthma and worsens 215 COVID-19 progression. Previous studies indicated that interferon production by bronchial 216 epithelial cells and plasmacytoid dendritic cells is deficient in asthmatics. [23] [24] [25] It is difficult to 217 estimate how this impaired antiviral immunity influences the course of COVID-19 because 218 severe cases of COVID-19 were reported to be related to overactive immune responses such 219 as cytokine storms. 26 However, the impaired innate immune response may dampen host 220 protection against SARS-CoV-2 and could result in severe COVID-19. In addition, the 221 possible mechanism of poor prognosis of COVID-19 in asthma is asthma exacerbation 222 caused by SARS-CoV-2. The link between respiratory viral infection and asthma 223 exacerbation is well established. 27 Rhinovirus is the most commonly associated virus, but 224 other viruses, including coronavirus are also identified, although less frequently. 28,29 As with 225 other coronaviruses, SARS-CoV-2 is anticipated to similarly exacerbate asthma, but it is uncertain whether the virus can aggravate asthma itself or bronchoconstriction. The precise 227 pathogenic mechanism of exacerbation due to SARS-CoV-2 has not yet been clearly 228 characterized, but the pneumonic manifestations of COVID-19 may have a more critical 229 influence on patients with chronic airway diseases, such as asthma, because they have less 230 pulmonary reservoirs than normal healthy individuals. 231

Our study also indicates a higher risk of severe outcomes of COVID-19 in patients with 232 asthma having a recent history of exacerbation of emergency room (ER) visits within one 233

year. These data implicate the importance of asthma control in mitigating the risk of severe 234 COVID-19. In the daily practice of patients with asthma, ICS are the main stem of 235 pharmacologic treatment to achieve and maintain asthma control. Corticosteroid use might 236 affect the outcome of COVID-19, but it is not determined whether corticosteroids, either 237

inhaled or systemic, are beneficial or harmful for COVID-19. There is a general concern that 238 corticosteroids may induce suppression of the host immunologic defense response to the virus, showed higher mortality of COVID-19, but asthma was not a risk factor for poor prognosis of 259 COVID-19. 36 Unlike these studies, we found the asthma morbidity led to poor prognosis of 260 COVID-19 even after multivariate analysis. Different working definition of asthma and 261 different methods of outcome evaluation of COVID-19 may affect the discrepancy of studies. 262

We included wider range of subjects with asthma who had a history of asthma symptoms and 263 medication in last 3 years. A strength of our study differentiated from other studies was the 264 grading system of COVID-19 severity using the demand of oxygen supply and mechanical 265 ventilation. We also performed survival analysis of mortality and subgroup analysis in the 266 elderly to validate our results. Further investigations are needed to elucidate the association 267 between asthma morbidity and COVID-19 severity in larger different populational data. 268

Our study has several limitations. First, the patients in our study had a confirmed diagnosis 269 for COVID-19 limiting our evaluation for the association between asthma morbidity and 270 susceptibility to COVID-19. Second, we could not evaluate the detailed clinical 271 characteristics, phenotypes, and severity of asthma in the patients with asthma because the 272 claim data did not include symptom control status, laboratory findings, and lung functions. J o u r n a l P r e -p r o o f 

Plasma IP-10 and MCP-3 levels are highly associated with 324 disease severity and predict the progression of COVID-19

World Health Organization, Weekly epidemiological update -29

Baseline Characteristics and Outcomes of 1591

Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Hospitalization Rates and Characteristics of Patients 333 Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 334 14 States

Community study of role of viral 372 infections in exacerbations of asthma in 9-11 year old children

Regional, age and respiratory-secretion-specific 375 prevalence of respiratory viruses associated with asthma exacerbation: a literature 376 review

Therapeutic 378 potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases

Identification of Antiviral Drug Candidates against SARS-381

CoV-2 from FDA-Approved Drugs

Molecular pharmacology of ciclesonide against 383 SARS-CoV-2

The peripheral lymphocyte count as a predictor of 385 severe COVID-19 and the effect of treatment with ciclesonide

One or more (≥1) 3,756 (49.5%) 505 (66.1%)

*P-value for Fisher's exact test, other P-values were derived from the chi-squared tests